Form 4 - Statement of changes in beneficial ownership of securities:
SEC Accession No. 0000905148-26-000281
Filing Date
2026-01-21
Accepted
2026-01-21 16:02:10
Documents
1
Period of Report
2026-01-17

Document Format Files

Seq Description Document Type Size
1 form4.html 4  
1 form4.xml 4 3036
  Complete submission text file 0000905148-26-000281.txt   4417
Mailing Address 480 ARSENAL WAY, SUITE 100 WATERTOWN MA 02472
Business Address 480 ARSENAL WAY, SUITE 100 WATERTOWN MA 02472 617-207-8979
Acrivon Therapeutics, Inc. (Issuer) CIK: 0001781174 (see all company filings)

EIN.: 825125532 | Fiscal Year End: 1231
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)

Mailing Address C/O ACRIVON THERAPEUTICS, INC. 480 ARSENAL WAY, SUITE 100 WATERTOWN MA 02472
Business Address
Miller Mary (Reporting) CIK: 0001841088 (see all company filings)

Type: 4 | Act: 34 | File No.: 001-41551 | Film No.: 26547754